Rami Manochakian, Thoracic Medical Oncologist at Mayo Clinic and Vice President of the North American Neuroendocrine Tumor Society, shared a post on X:
“Hot Off The Press
U.S. FDA approves:
Maintenance Lurbinectedin (in combination with Atezolizumab) as maintenance Treatment after 1st line induction for:
- Extensive Stage Small Cell Lung Cancer.
Approval is based on:
- IMforte trial.”
Read Rami’s previous post.
More posts featuring Rami Manochakian.
